Cara Therapeutics
Cara Therapeutics shares data from part a of notalgia paresthetica trial
June 13, 2024Research and Development Cara Therapeutics, Neurology, clinical trial, notalgia paresthetica, pruritus
Cara Therapeutics has announced the outcome from the dose-finding Part A of the KOURAGE-1 study which assessed the efficacy and …
FDA grants Priority Review to Korsuva for CKD-associated pruritis
March 8, 2021Sales and Marketing Cara Therapeutics, FDA, Korsuva
The FDA has accepted and granted Priority Review for the new drug application (NDA) for Cara Therapeutics’ Korsuva (difelikefalin) solution …
Vifor Fresenius snap up rights to Cara’s itch therapy
May 23, 2018Research and Development, Sales and Marketing Cara Therapeutics, Vifor Fresenius, biotech, drugs, pharma, pharmaceutical
The joint partnership between Vifor Pharma and Fresenius Medical Care, Vifor Fresenius, has put down $50 in upfront cash and …
Latest content
FibroFind appoints Lee Borthwick as CEO
July 21, 2026
